First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors - Concepedia

Concepedia

Publication | Open Access

First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors

DOI Full Paper Access

88

Citations

20

References

2022

Year

Elizabeth J. Davis, Juan Martín-Liberal, Rebecca Kristeleit, Daniel C. Cho, Sarah P. Blagden, Dominik Berthold, Dana B. Cardin, María Vieito, Rowan Miller, Prashanth Hari Dass,

Journal for ImmunoTherapy of Cancer

Abstract

NCT02923349.

References

	Year	Citations

Page 1